SAN DIEGO, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development ...

SAN DIEGO, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (RXDX) (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, ...

- The event will feature Prometheus management and key opinion leader presentations on PR600 target unveiling, scientific rationale, and corresponding therapeutic candidate, PRA052 - - PRA052 is a ...

Prometheus Biosciences also announced it was selling $250 million in stock to raise funds. The company said it plans to put its lead therapy into phase 3 trials next year. Prometheus Biosciences hit a ...

SAN DIEGO, March 3, 2021 /PRNewswire/ -- Prometheus Biosciences, Inc. ("Prometheus"), a biotechnology company pioneering a precision medicine approach for the discovery, development, and ...

Prometheus Biosciences Inc RXDX shares are trading higher Thursday after multiple analyst firms raised price targets on the stock following positive results from the company's PRA023 in both ...

Merck announced Sunday morning that it is purchasing Prometheus Biosciences for nearly $11 billion. As part of the definitive agreement, Merck will acquire Prometheus’ lead candidate, PRA023, an anti ...

Prometheus Biosciences stock shot up more than 180% in a single day after reporting encouraging clinical trial results for its lead candidate. Prometheus Biosciences is developing a potential first-in ...

Shares of Prometheus Biosciences soared 70% in premarket trading on Monday after Merck & Co. announced that it would acquire the company in a $10.8 billion deal. The deal, announced Sunday, gives ...

SAN DIEGO, May 09, 2023 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (RXDX) (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, ...